FDA WARNING_LETTER - Sun Pharmaceutical Industries Ltd. - September 19, 2014

The FDA issued a Warning Letter to Sun Pharmaceutical Industries Ltd. in Halol, Gujarat, India, following a September 8-19, 2014, inspection. The inspection revealed significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations include: 1. **Aseptic Processing Deficiencies (21 CFR 211.113(b)):** Failure to establish and follow procedures to prevent microbiological contamination. This involved inadequate unidirectional airflow studies (smoke studies) under dynamic conditions, indicating poor aseptic processing equipment design and lack of dynamic simulation for critical interventions. Additionally, media fill runs had rejected vials without written justification, and challenging conditions were not adequately defined or justified. 2. **Facility Maintenance (21 CFR 211.42(c)(10)(iv) and (i)):** Floors, walls, and ceilings in aseptic areas were not smooth, hard, or easily cleanable, with observed leaks, water stains, and ceiling damage in the parenteral manufacturing area. 3. **Inadequate Investigations (21 CFR 211.192):** Failure to thoroughly investigate out-of-specification (OOS) results, such as unknown impurities in stability tests, and extraneous peaks in cleaning validation reports, without identifying root causes or extending investigations to all affected batches.